Literature DB >> 23545529

Safety and tolerability of luliconazole solution 10-percent in patients with moderate to severe distal subungual onychomycosis.

T Jones1, A Tavakkol.   

Abstract

The study objective was to evaluate the safety, tolerability, systemic exposure, and pharmacokinetics (PK) of 10% luliconazole solution (luliconazole) when topically applied once daily to all 10 toenails and periungual areas in patients with moderate to severe distal subungual onychomycosis. In this single-center, open-label study, 24 patients applied 20 mg/ml of luliconazole (twice the clinical dose) for 29 days with a 7-day follow-up. Complete PK profiles were determined on days 1, 8, 15, and 29. Safety/tolerability assessments included application site reactions, adverse events, vital signs, clinical laboratory findings, and electrocardiograms. Mean luliconazole plasma concentrations remained around the lower limit of quantitation (0.05 ng/ml) and were comparable on days 8, 15, and 29 (range, 0.063 to 0.090 ng/ml), suggesting steady state occurred by day 8. Every patient had undetectable plasma luliconazole levels for at least 11% of the time points, and 12 of the 24 patients had undetectable levels for at least 70% of the time points. The maximum plasma concentration of luliconazole (C(max)) observed in any patient was 0.314 ng/ml and the maximum area under the concentration-time curve from 0 to 24 h (AUC0-24) was 4.34 ng · h/ml. Five patients (21%) had measureable luliconazole levels in the plasma 7 days after the last dose. The median concentration of luliconazole in the nail at this time point was 34.65 mg/g (from 42 of 48 collected toenail samples). There was one mild incidence of skin erythema on day 5 that resolved on day 8, there were no reports of drug-induced systemic side effects, and there was no evidence of QT prolongation. Luliconazole, when applied once daily to all 10 fungus-infected toenails for 29 days, is generally safe and well tolerated and results in significant accumulation of drug in the nail. Systemic exposure is very low, with no evidence of drug accumulation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23545529      PMCID: PMC3716121          DOI: 10.1128/AAC.02370-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Health-related quality of life in patients with nail disorders.

Authors:  Adam Reich; Jacek C Szepietowski
Journal:  Am J Clin Dermatol       Date:  2011-10-01       Impact factor: 7.403

2.  Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis.

Authors:  Hiroyasu Koga; Yasuko Nanjoh; Hideo Kaneda; Hideyo Yamaguchi; Ryoji Tsuboi
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  In vitro antifungal activity of luliconazole against clinical isolates from patients with dermatomycoses.

Authors:  Hiroyasu Koga; Yuri Tsuji; Kazuyoshi Inoue; Kazuo Kanai; Toshiro Majima; Tatsuya Kasai; Katsuhisa Uchida; Hideyo Yamaguchi
Journal:  J Infect Chemother       Date:  2006-06       Impact factor: 2.211

Review 4.  Toenail onychomycosis: current and future treatment options.

Authors:  Justin J Finch; Erin M Warshaw
Journal:  Dermatol Ther       Date:  2007 Jan-Feb       Impact factor: 2.851

Review 5.  Toenail onychomycosis: an important global disease burden.

Authors:  J Thomas; G A Jacobson; C K Narkowicz; G M Peterson; H Burnet; C Sharpe
Journal:  J Clin Pharm Ther       Date:  2010-10       Impact factor: 2.512

Review 6.  Update in antifungal therapy of dermatophytosis.

Authors:  Aditya K Gupta; Elizabeth A Cooper
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

7.  Health-related quality of life and nail disorders.

Authors:  Stefano Tabolli; Livia Alessandroni; Jeanette Gaido; Francesca Sampogna; Cristina Di Pietro; Damiano Abeni
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

8.  In vitro antifungal activity of luliconazole (NND-502), a novel imidazole antifungal agent.

Authors:  Katsuhisa Uchida; Yayoi Nishiyama; Hideyo Yamaguchi
Journal:  J Infect Chemother       Date:  2004-08       Impact factor: 2.211

9.  In vitro antifungal activities of luliconazole, a new topical imidazole.

Authors:  Hiroyasu Koga; Yasuko Nanjoh; Koichi Makimura; Ryoji Tsuboi
Journal:  Med Mycol       Date:  2009       Impact factor: 4.076

10.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

Authors:  Boni Elewski; Amir Tavakkol
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

View more
  8 in total

1.  Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.

Authors:  Nathan P Wiederhold; Annette W Fothergill; Dora I McCarthy; Amir Tavakkol
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

2.  Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis.

Authors:  Mahdi Abastabar; Iman Haghani; Tahereh Shokohi; Mohammad Taghi Hedayati; Seyed Reza Aghili; Ali Jedi; Sulmaz Dadashi; Shafigheh Shabanzadeh; Tahereh Hosseini; Narges Aslani; Jacques F Meis; Hamid Badali
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 3.  Newer Topical Treatments in Skin and Nail Dermatophyte Infections.

Authors:  Kanika Sahni; Sanjay Singh; Sunil Dogra
Journal:  Indian Dermatol Online J       Date:  2018 May-Jun

Review 4.  Therapy of Skin, Hair and Nail Fungal Infections.

Authors:  Roderick Hay
Journal:  J Fungi (Basel)       Date:  2018-08-20

5.  Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.

Authors:  Bertrand Nyuykonge; Wilson Lim; Lukas van Amelsvoort; Alexandro Bonifaz; Ahmed Fahal; Hamid Badali; Mahdi Abastabar; Annelies Verbon; Wendy van de Sande
Journal:  Mycoses       Date:  2022-05-06       Impact factor: 4.931

6.  Formulation and Development of a Water-in-Oil Emulsion-Based Luliconazole Cream: In Vitro Characterization and Analytical Method Validation by RP-HPLC.

Authors:  Vijay Kumar Panthi; Utsav Nepal
Journal:  Int J Anal Chem       Date:  2022-09-23       Impact factor: 1.698

Review 7.  Luliconazole for the treatment of fungal infections: an evidence-based review.

Authors:  Deepshikha Khanna; Subhash Bharti
Journal:  Core Evid       Date:  2014-09-24

Review 8.  Onychomycosis: A Review.

Authors:  Bianca Maria Piraccini; Aurora Alessandrini
Journal:  J Fungi (Basel)       Date:  2015-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.